FDA Brief

Warning letters Drugs

FDA warning letter to

Viv Health, Inc. dba VIV RX

MediumIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

What happened

FDA reviewed the website https://www.vivrx.com in December 2025 and found it offers compounded semaglutide and tirzepatide drug products. The labels pictured on the site show "VIV RX," which suggests VIV RX is the compounder of those drugs when it is not. FDA says those representations are false or misleading, so the products are misbranded.

What FDA found

  1. The website labels name VIV RX as if it made the compounded drugs, when it did not, which makes the labeling false or misleading.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)
  2. Advertising or promoting a compounded drug with false or misleading claims misbrands that drug.

    FDCA § 502(bb) [21 U.S.C. § 352(bb)]
  3. Sending these misbranded drugs across state lines is a prohibited act.

    FDCA § 301(a) [21 U.S.C. § 331(a)]
  4. Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.

    FDCA § 301(c) [21 U.S.C. § 331(c)]
  5. The semaglutide and tirzepatide products are "new drugs" not generally recognized as safe and effective, and compounded drugs must meet the conditions of section 503A or 503B to be exempt from new drug approval requirements.

    FDCA §§ 201(p), 503A, 503B [21 U.S.C. §§ 321(p), 353a, 353b]

What FDA wants

Within 15 working days, VIV RX must send a written response to FDA's Office of Compounding Quality and Compliance describing the steps taken to fix the violations and prevent recurrence. The response should identify who actually produces the compounded products, include sample labeling, and address or correct the other website claims.

Who should pay attention

  • telehealth platforms that market compounded semaglutide and tirzepatide
  • compounding pharmacies whose products are sold under a marketer's name
  • marketers and brands that put their own name on drug labels they do not manufacture

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low